1. Home
  2. MLYS vs BAND Comparison

MLYS vs BAND Comparison

Compare MLYS & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.05

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Bandwidth Inc.

BAND

Bandwidth Inc.

HOLD

Current Price

$52.79

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
BAND
Founded
2019
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.3B
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
MLYS
BAND
Price
$26.05
$52.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$48.67
$24.50
AVG Volume (30 Days)
653.2K
1.2M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
$204,113,000.00
Revenue This Year
N/A
$15.16
Revenue Next Year
N/A
$6.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.26
52 Week Low
$14.26
$12.50
52 Week High
$47.65
$79.08

Technical Indicators

Market Signals
Indicator
MLYS
BAND
Relative Strength Index (RSI) 42.61 48.60
Support Level $25.25 $48.15
Resistance Level $30.90 $77.53
Average True Range (ATR) 1.11 3.44
MACD -0.09 1.01
Stochastic Oscillator 32.27 90.25

Price Performance

Historical Comparison
MLYS
BAND

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.

Share on Social Networks: